Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
10.8M
-
Number of holders
-
21
-
Total 13F shares, excl. options
-
1.08M
-
Shares change
-
+30K
-
Total reported value, excl. options
-
$5.23M
-
Value change
-
+$124K
-
Put/Call ratio
-
0.05
-
Number of buys
-
9
-
Number of sells
-
-10
-
Price
-
$4.83
Significant Holders of Lantern Pharma Inc. - Common Stock, par value $0.0001 per share (LTRN) as of Q1 2023
28 filings reported holding LTRN - Lantern Pharma Inc. - Common Stock, par value $0.0001 per share as of Q1 2023.
Lantern Pharma Inc. - Common Stock, par value $0.0001 per share (LTRN) has 21 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.08M shares
of 10.8M outstanding shares and own 10.05% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (367K shares), NewEdge Advisors, LLC (172K shares), CARLSON CAPITAL L P (125K shares), CM Management, LLC (60K shares), GEODE CAPITAL MANAGEMENT, LLC (57.8K shares), Redmond Asset Management, LLC (49.2K shares), HORIZON KINETICS ASSET MANAGEMENT LLC (30K shares), STATE STREET CORP (27.8K shares), UBS Group AG (27K shares), and Bank of New York Mellon Corp (26.5K shares).
This table shows the top 21 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.